In conclusion, overexpression of c-Jun in CAR T cells avoided phenotypic and functional T cell exhaustion and accordingly increased anti-tumor control in several preclinical xenograft mouse models, which encourages clinical testing of Jun+ CAR T cells in the future. Here, JUN is linked to neoplasm.